Elevation Oncology, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 45.7 million compared to USD 95.08 million a year ago. Basic loss per share from continuing operations was USD 1.34 compared to USD 4.09 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.145 USD | +1.84% | +7.55% | +669.09% |
02:07pm | Piper Sandler Starts Elevation Oncology With Overweight Rating, $10 Price Target | MT |
May. 14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+669.09% | 222M | |
+10.96% | 114B | |
+10.60% | 105B | |
-4.84% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-16.90% | 16.13B | |
+2.21% | 13.75B | |
+31.54% | 11.76B |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023